Has Earl Craven received payments from drug or device companies?

Yes. Drug and device makers reported $120,144 in general payments to Earl Craven across 114 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Earl Craven did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Earl Craven come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Earl Craven

Ophthalmology · Baltimore, MDNPI 1457354821

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $92,300 of the $120,144 with a category attached, or 76.8%. AbbVie accounts for 69.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $86,701 and has fallen 99.8% since, to $174 in 2023. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$120,144in general payments, 2019–2025

Across 114 payments — averaging $1053.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$84K
W. L. Gore & Associates, Inc.$23K
Aerie Pharmaceuticals, Inc.$10K
Sight Sciences, Inc.$2K
Alcon Research LLC$700
Mobius Therapeutics, LLC$500
plus $99 from 2 others

$194,943in research payments, 2019–2025

Across 3 payments — averaging $64,981 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$195K

What the payments were for

Consulting fees$92,30077%
Speaking & faculty fees$12,49010%
Travel & lodging$12,76311%
Food & beverage$2,5912%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	69	$83,502
W. L. Gore & Associates, Inc.	22	$22,724
Aerie Pharmaceuticals, Inc.	11	$10,370
Sight Sciences, Inc.	2	$2,250
Alcon Research LLC	1	$700
Mobius Therapeutics, LLC	1	$500
Ivantis, Inc	2	$65
Haag-streit USA, Inc.	6	$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XEN$23,677
Product in Development$22,559
Rocklatan$10,204
DURYSTA$8,625
OMNI$2,250
CyPass$700
Mitosol$500
LUMIGAN$104

How this compares

$120,144 in reported general payments places this provider in the 95th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland →

Other ophthalmology in Baltimore

Alfred SommerBaltimore$2.9M
Richard AdlerBaltimore$2.7M
Peter McDonnellBaltimore$1.4M
Esen AkpekBaltimore$782K
Neil BresslerBaltimore$265K
Adrienne ScottBaltimore$170K
Jennifer ThorneBaltimore$128K
Peter CampochiaroBaltimore$103K
Gail SchwartzBaltimore$85K
John GottschBaltimore$71K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →